Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.45 USD | -2.02% |
|
-0.97% | -65.24% |
28/06 | Barclays Cuts Price Target on 10x Genomics to $24 From $36, Maintains Overweight Rating | MT |
27/06 | Wolfe Research Downgrades 10x Genomics to Peer Perform From Outperform | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.24% | 232.83Cr | |
-11.78% | 1.12TCr | |
-13.76% | 729.18Cr | |
+29.50% | 556.51Cr | |
-0.19% | 531.31Cr | |
-19.19% | 368.03Cr | |
+7.62% | 258.29Cr | |
-10.48% | 222.66Cr | |
+27.80% | 221.38Cr | |
-19.12% | 157.21Cr |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- Transcript : 10x Genomics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 10